Literature DB >> 8102517

c-erbB-2 oncogene related to p53 expression, cell proliferation and prognosis in breast cancer.

H J Lipponen1, S Aaltomaa, S Syrjänen, K Syrjänen.   

Abstract

A series of 193 archival breast cancer biopsies were analysed immunohistochemically to detect over-expression of c-erbB-2 oncoprotein. Altogether, 59/193 (31%) of the tumours were positive for c-erbB-2, the staining being located at the cell membranes with weak cytoplasmic staining in some samples. The expression of c-erbB-2 was positively correlated with a number of parameters analysed: ductal type, intraductal growth pattern, high tumour grade, density of tumour infiltrating lymphocytes (TIL), DNA aneuploidy, steroid (ER, PR) receptor negativity, high S-phase fraction, high mitotic frequency, high values of nuclear factors, and accumulation of p53 protein. c-erbB-2 expression showed a weak association with a low survival probability (p = 0.07) and with a short recurrence-free survival (p = 0.1). In local tumours or in axillary lymph node positive tumours, c-erB-2 expression had no significant prognostic value. Also in multivariate analysis, c-erbB-2 expression had no independent prognostic value superior to the axillary lymph node status, tumour diameter and mitotic frequency. The results show that c-erbB-2 expression in related to several histopathological features of malignancy and cell proliferation in breast cancer, but it has no independent prognostic value better than that of the established prognostic factors.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8102517

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  Biological indices in the assessment of breast cancer.

Authors:  A S Leong; A K Lee
Journal:  Clin Mol Pathol       Date:  1995-10

Review 2.  Complexity of signal transduction mediated by ErbB2: clues to the potential of receptor-targeted cancer therapy.

Authors:  P Nagy; A Jenei; S Damjanovich; T M Jovin; J Szölôsi
Journal:  Pathol Oncol Res       Date:  1999       Impact factor: 3.201

3.  Status of epidermal growth factor receptors family in hormone-dependent carcinomas of the breast and prostate with reference to serum lipids and lipoproteins.

Authors:  D Jain; A Ray; A K Bahadur; K U Chaturvedi; R Sood; S Sharma; S L Naik; B K Sharma
Journal:  Indian J Clin Biochem       Date:  2001-01

4.  Coexpression of HER-2/neu and p53 is associated with a shorter disease-free survival in node-positive breast cancer patients.

Authors:  C Wiltschke; I Kindas-Muegge; A Steininger; A Reiner; G Reiner; P N Preis
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

5.  c-erbB-2 oncoprotein detected by automated quantitative immunocytochemistry in breast carcinomas correlates with patients' overall and disease-free survival.

Authors:  C Charpin; S Garcia; C Bouvier; F Martini; M N Lavaut; C Allasia; P Bonnier; L Andrac
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.